MannKind (MNKD) 10-Q10 Nov 142014 Q3 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2014	Nov. 03, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'MNKD	'
Entity Registrant Name	'MANNKIND CORP	'
Entity Central Index Key	'0000899460	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	405,699,862

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$172,465	$70,790
State research and development tax credit exchange receivable - current	803	'
Prepaid expenses and other current assets	20,253	5,485
Total current assets	193,521	76,275
Property and equipment - net	190,923	176,557
State research and development credit exchange receivable	260	298
Other assets	2,114	5,516
Total	386,818	258,646
Current liabilities:	'	'
Accounts payable	17,389	3,860
Accrued expenses and other current liabilities	27,269	21,634
Facility financing obligation	'	102,300
Senior convertible notes - current	99,120	'
Deferred up-front payment from collaboration agreement	150,000	'
Total current liabilities	293,778	127,794
Facility financing obligation	72,625	'
Senior convertible notes	'	98,439
Note payable to principal stockholder	49,521	49,521
Other liabilities	11,572	13,605
Total liabilities	427,496	289,359
Commitments and contingencies	'	'
Stockholders' deficit:	'	'
Undesignated preferred stock, $0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at September 30, 2014 and December 31, 2013	'	'
Common stock, $0.01 par value - 550,000,000 shares authorized at September 30, 2014 and December 31, 2013; 405,469,034 and 369,391,972 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively	4,055	3,697
Additional paid-in capital	2,413,621	2,261,996
Accumulated other comprehensive loss	-11	-4
Deficit accumulated during the development stage	-2,458,343	-2,296,402
Total stockholders' deficit	-40,678	-30,713
Total	$386,818	$258,646

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Undesignated preferred stock, par value	$0.01	$0.01
Undesignated preferred stock, shares authorized	10,000,000	10,000,000
Undesignated preferred stock, shares issued	0	0
Undesignated preferred stock, shares outstanding	0	0
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	550,000,000	550,000,000
Common stock, shares issued	405,469,034	369,391,972
Common stock, shares outstanding	405,469,034	369,391,972

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended		283 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014
Revenue	'	'	'	'	$3,166
Operating expenses:	'	'	'	'	'
Research and development	19,178	27,281	82,684	80,731	1,659,976
General and administrative	19,088	17,481	66,840	42,053	552,226
In-process research and development costs	'	'	'	'	19,726
Goodwill impairment	'	'	'	'	151,428
Total operating expenses	38,266	44,762	149,524	122,784	2,383,356
Loss from operations	-38,266	-44,762	-149,524	-122,784	-2,380,190
Other income (expense)	7,898	10	1,638	48	-1,264
Interest expense on note payable to principal stockholder	-729	-1,745	-2,164	-5,123	-47,298
Interest expense on notes	-5,424	-4,323	-11,895	-10,052	-66,981
Interest income	1	2	4	4	37,008
Loss before benefit for income taxes	-36,520	-50,818	-161,941	-137,907	-2,458,725
Income tax benefit	'	'	'	'	382
Net loss	-36,520	-50,818	-161,941	-137,907	-2,458,343
Deemed dividend related to beneficial conversion feature of convertible preferred stock	'	'	'	'	-22,260
Accretion on redeemable preferred stock	'	'	'	'	-952
Net loss applicable to common stockholders	($36,520)	($50,818)	($161,941)	($137,907)	($2,481,555)
Net loss per share applicable to common stockholders - basic and diluted	($0.09)	($0.17)	($0.42)	($0.48)	'
Shares used to compute basic and diluted net loss per share applicable to common stockholders	394,163	296,386	381,332	286,889	'

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended		283 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014
Net loss	($36,520)	($50,818)	($161,941)	($137,907)	($2,458,343)
Other comprehensive loss:	'	'	'	'	'
Cumulative translation (loss) gain	-7	-1	-7	-3	-11
Unrealized gain (loss) on investments:	'	'	'	'	'
Unrealized holding gain (loss) during the period	'	'	'	'	48
Less: reclassification adjustment for gains (losses) included in net loss	'	'	'	'	-48
Net unrealized gain on investments	'	'	'	'	'
Other comprehensive loss	-7	-1	-7	-3	-11
Comprehensive loss	($36,527)	($50,819)	($161,948)	($137,910)	($2,458,354)

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended		283 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'	'
Net loss	($161,941)	($137,907)	($2,458,343)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:	'	'	'
Depreciation and accretion	15,574	10,109	156,408
Stock-based compensation expense	46,755	31,304	229,859
Stock expense for shares issued pursuant to research agreement	'	'	3,018
(Gain) loss on sale, abandonment/disposal or impairment of property and equipment	'	686	25,070
Accrued interest on investments, net of amortization of discounts	'	'	-191
In-process research and development	'	'	19,726
Goodwill impairment	'	'	151,428
Loss on available-for-sale securities	'	'	990
Write-off of derivative liability	-363	'	-363
Litigation settlement in stock	'	'	6,494
Fair value of forward purchase contract	'	'	1,237
Interest expense related to milestone payment	1,850	'	1,850
Other, net	-7	-3	1,094
Changes in assets and liabilities:	'	'	'
State research and development credit exchange receivable	-765	242	-1,062
Prepaid expenses and other current assets	-14,768	-708	-18,303
Other assets	-130	'	-360
Accounts payable	13,692	-1,929	17,039
Accrued expenses and other current liabilities	-3,003	3,525	35,721
Deferred up-front payment from collaboration agreement	150,000	'	150,000
Other liabilities	2,186	'	2,775
Net cash provided by (used in) operating activities	39,830	-94,681	-1,685,163
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'	'
Purchase of marketable securities	'	'	-796,779
Sales and maturities of marketable securities	'	'	796,393
Purchase of property and equipment	-19,134	-1,821	-354,867
Proceeds from sale of property and equipment	'	'	454
Net cash used in investing activities	-9,884	-1,821	-345,549
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Issuance of common stock and warrants, net of issuance costs	38,573	51,658	1,582,897
Collection of Series C convertible preferred stock subscriptions receivable	'	'	50,000
Issuance of Series B convertible preferred stock for cash	'	'	15,000
Cash received for common stock to be issued	'	'	3,900
Repurchase of common stock	'	'	-1,028
Put shares sold to majority stockholder	'	'	623
Borrowings under lines of credit	'	'	4,220
Payment of 2013 notes	'	'	-115,000
Proceeds from notes receivables	'	'	1,742
Proceeds from issuance of facility financing obligation & milestone rights	40,000	79,500	159,500
Proceeds from issuance of Tranche B of the facility financing obligation	20,000	'	20,000
Facility financing obligation & milestone rights issuance costs	'	-598	-598
Borrowings on notes payable to principal stockholder	'	'	387,750
Principal payments on notes payable to principal stockholder	'	'	-70,000
Borrowings on notes payable	'	'	3,460
Principal payments on notes payable	'	'	-1,667
Proceeds from senior convertible notes	'	'	207,050
Payment of employment taxes related to vested restricted stock units	-26,844	-2,095	-44,672
Net cash provided by financing activities	71,729	128,465	2,203,177
NET INCREASE IN CASH AND CASH EQUIVALENTS	101,675	31,963	172,465
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	70,790	61,840	'
CASH AND CASH EQUIVALENTS, END OF PERIOD	172,465	93,803	172,465
SUPPLEMENTAL CASH FLOWS DISCLOSURES:	'	'	'
Cash paid for income taxes	'	'	26
Interest paid in cash, net of amounts capitalized	9,740	7,862	82,344
Accretion on redeemable convertible preferred stock	'	'	-952
Issuance of common stock upon conversion of notes payable	'	'	3,331
Increase in additional paid-in capital resulting from merger	'	'	171,154
Issuance of common stock for notes receivable	'	'	2,758
Issuance of common stock pursuant to conversion of facility financing obligation	93,500	'	100,000
Issuance of put option by stockholder	'	'	-2,949
Put option redemption by stockholder	'	'	1,921
Issuance of Series C convertible preferred stock subscriptions	'	'	50,000
Issuance of Series A redeemable convertible preferred stock	'	'	4,296
Conversion of Series A redeemable convertible preferred stock	'	'	-5,248
Non-cash construction in progress and property and equipment	3,809	5,523	3,089
Capitalization of interest on note payable to principal stockholder	'	'	22,105
Reduction of principal on note payable to principal stockholder upon issuance of common stock and exercise of warrants	'	'	290,334
Forward purchase contract contribution to APIC	'	'	29,317
Reclassification of forward purchase contract to APIC	'	'	28,080
Reclassification of share-based awards to liability	22,963	'	22,963
Tranche B Commitment Asset	1,753	'	1,753
Intellectual property	'	'	'
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:	'	'	'
Income from sale of intellectual property	-9,250	'	-9,250
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'	'
Proceeds from sale of intellectual property	$9,250	'	$9,250

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (Parenthetical) (USD $)	283 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014
Conversion of convertible preferred stock amount converted	$5,248
Series B Preferred Stock	'
Conversion of convertible preferred stock amount converted	15,000
Series C Preferred Stock	'
Conversion of convertible preferred stock amount converted	$50,000

Description_of_business_and_ba

Description of business and basis of presentation	9 Months Ended
Description of business and basis of presentation	Sep. 30, 2014
Description of business and basis of presentation	'

	1. Description of business and basis of presentation

	The accompanying unaudited condensed consolidated financial statements of MannKind Corporation and its subsidiaries (“MannKind” or the “Company”), have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The information included in this quarterly report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2013 filed with the SEC on March 3, 2014 (the “Annual Report”).

	In the opinion of management, all adjustments, consisting only of normal, recurring adjustments, considered necessary for a fair presentation of the results of these interim periods have been included. Interim financial results may not be indicative of the results that may be expected for the full year.

	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates or assumptions. The more significant estimates reflected in these accompanying financial statements involve assessing long-lived assets for impairment, accrued expenses, including clinical study expenses, valuation of forward purchase contracts, valuation of the facility financing obligation, commitment asset, milestone rights, valuation of stock-based compensation and the determination of the provision for income taxes and corresponding deferred tax assets and liabilities and any valuation allowance recorded against net deferred tax assets. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.

	Business — The Company is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases such as diabetes. The Company’s lead product, AFREZZA (insulin human) inhalation powder, is a rapid-acting inhaled insulin that was approved by the U.S. Food and Drug Administration (“FDA”) on June 27, 2014 to improve glycemic control in adult patients with diabetes.

	Basis of Presentation — The Company is considered to be in the development stage as its primary activities since incorporation have been establishing its facilities, recruiting personnel, conducting research and development, business development, business and financial planning, and raising capital. It is costly to develop therapeutic products and conduct clinical studies for these products. From its inception through September 30, 2014, the Company had accumulated net losses of $2.5 billion, which include cumulative negative cash flow from operations of $1.7 billion and a goodwill impairment charge of $151.4 million.

	On August 11, 2014, the Company entered into a license and collaboration agreement (the “Sanofi License Agreement”) with Sanofi-Aventis Deutschland GmbH (which subsequently assigned its rights and obligations under the agreement to Sanofi-Aventis U.S. LLC (“Sanofi”)), pursuant to which Sanofi will be responsible for global commercial, regulatory and development activities for AFREZZA. Under the Sanofi License Agreement, the Company received a $150.0 million up-front fee and may earn up to an aggregate of $775.0 million upon the achievement of certain development, manufacturing, regulatory and sales milestones. Worldwide profits and losses with respect to AFREZZA will be shared 65% by Sanofi and 35% by the Company. Pursuant to a supply agreement, the Company will manufacture AFREZZA at its manufacturing facility in Danbury, Connecticut to supply Sanofi’s demand for the product. The Sanofi License Agreement became effective on September 23, 2014 following completion of the U.S. Federal Trade Commission’s review of the transactions contemplated by the Sanofi License Agreement under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder (the “Hart-Scott-Rodino Act”) and the completion of documentation related to the $175.0 million secured loan facility being provided to the Company by an affiliate of Sanofi (the “Sanofi Loan Facility”) to fund the Company’s share of net losses under the Sanofi License Agreement.

	At September 30, 2014, the Company’s capital resources consisted of cash and cash equivalents of $172.5 million. The Company expects to continue to incur significant expenditures to support commercial launch of AFREZZA and the development of other product candidates as contemplated under the Sanofi License Agreement. In addition, the Company’s 5.75% Senior Convertible Notes due 2015 (the “2015 notes”) in the aggregate principal amount of $100.0 million have a maturity date of August 15, 2015, and payment on the outstanding amount is due in full on that date (see Note 10 – Senior convertible notes).



	The Company may need to raise additional capital, whether through the sale of equity or debt securities, additional strategic business collaborations, the establishment of other funding facilities, licensing arrangements, asset sales or other means. Additional funding sources that are, or in certain circumstances may be available to the Company, include approximately $30.1 million principal amount of available borrowings under its loan arrangement ( the “Loan Arrangement”) with The Mann Group LLC (“The Mann Group”) (see note 9 – Related-party arrangements), potential proceeds from the exercise of warrants issued in its February 2012 public offering of approximately $20 million, the Company’s at-the-market issuance sales agreements which allow the Company to sell up to $50 million in common stock, and pursuant to the facility agreement (the “Facility Agreement”) with Deerfield Private Design Fund II, L.P. (“Deerfield Private Design Fund”) and Deerfield Private Design International II, L.P. (collectively, “Deerfield”) and the First Amendment to Facility Agreement and Registration Rights Agreement (the “First Amendment”) additional sales of an additional tranche of notes (the “Tranche B notes”) of up to $70 million which must be purchased prior to December 30, 2014 (see Note 11 – Facility Agreement).

	Although we believe that our existing cash and cash equivalents and available debt financing will be sufficient to finance our operational cash needs through at least the next twelve months, should our results not meet our current operating plan, it could negatively impact our liquidity and we may need to raise additional capital or seek additional financing sources as discussed above. There can be no assurance that we would be able to raise such additional financing or additional capital on acceptable terms, or at all, and if we are not able to raise adequate additional financing or capital to continue to fund our ongoing operations, we will need to defer, reduce or eliminate significant planned expenditures or significantly curtail our operations, and there may be substantial doubt about our ability to continue as a going concern.

	Prepaid expenses and other current assets — Prepaid expenses and other current assets primarily consist of prepaid expenses for goods and services to be received. As of September 30, 2014, prepaid and other current assets had a balance of $20.3 million, mainly comprised of a $15.0 million prepayment for 2015 quantities of insulin, prepaid insurance, and prepaid clinical trial expenses.

	On July 31, 2014, the Company entered into a Supply Agreement (the “Supply Agreement”) with Amphastar France Pharmaceuticals S.A.S., a French corporation (“Amphastar”), pursuant to which Amphastar will manufacture for and supply to the Company certain quantities of recombinant human insulin for use in AFREZZA. Under the terms of the Supply Agreement, Amphastar will be responsible for manufacturing the insulin in accordance with the Company’s specifications and agreed-upon quality standards. The Company has agreed to purchase annual minimum quantities of insulin under the Supply Agreement of an aggregate of approximately €120.1 million in calendar years 2015 through 2019. The Company may request to purchase additional quantities of insulin over such annual minimum quantities. As part of the Supply Agreement, the Company paid a $15.0 million deposit to Amphastar as prepayment for 2015 quantities of insulin.

	Unless earlier terminated, the term of the Supply Agreement expires on December 31, 2019 and can be renewed for additional, successive two year terms upon 12 months’ written notice, given prior to the end of the initial term or any additional two year term. The Company and Amphastar each have normal and customary termination rights, including termination for material breach that is not cured within a specific time frame or in the event of liquidation, bankruptcy or insolvency of the other party. In addition, the Company may terminate the Supply Agreement upon two years’ prior written notice to Amphastar without cause or upon 30 days’ prior written notice to Amphastar if a controlling regulatory authority withdraws approval for AFREZZA, provided, however, in the event of a termination pursuant to either of the latter two scenarios, the provisions of the Supply Agreement require the Company to pay the full amount of all unpaid purchase commitments due over the initial term within 60 calendar days of the effective date of such termination.

	Sale of intellectual property — On July 18, 2014, the Company entered into an assignment agreement with a third party whereby the third party acquired all proprietary rights, technology and know-how that related to a small molecule inhibitor compound and all pre-clinical data and results related thereto. Under the terms of the assignment agreement, the Company received total consideration of $9.3 million, which was offset by $1.4 million of expense associated with the sale of the intellectual property related to oncology.

	Fair Value of Financial Instruments — The carrying amounts reported in the accompanying financial statements for cash and cash equivalents, accounts payable and accrued liabilities approximate their fair value due to their relatively short maturities. The fair value of the cash equivalents, note payable to related party, senior convertible notes, and the elements of the Facility Agreement are discussed in Note 13, “Fair value of financial instruments.”

	Recently Issued Accounting Standards — In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force). The amendments in this ASU provide guidance on the financial statements presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. An unrecognized tax benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward with certain exceptions, in which case such an unrecognized tax benefit should be presented in the financial statements as a liability. The amendments in this ASU do not require new recurring disclosures. The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The adoption of the new requirement did not have a significant impact on the Company’s consolidated financial statements.

	In May 2014, a new standard was issued related to revenue recognition, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The new standard will replace most of the existing revenue recognition standards in U.S. GAAP when it becomes effective on January 1, 2017. Early adoption is not permitted. The new standard allows for either “full retrospective” adoption, whereby the new standard is applied to each prior reporting period presented or “modified retrospective” adoption, whereby the new standard is only applied to the most current period presented with the cumulative effect of the change recognized at the date of the initial application. The Company is assessing the potential impact of the new standard on its consolidated statements of financial position and results of operations and comprehensive income (loss) and has not yet selected a transition method.

	In June 2014, the FASB issued ASU No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. The amendments in this ASU remove all incremental financial reporting requirements from GAAP for development stage entities, including the removal of Topic 915, Development Stage Entities, from the FASB Accounting Standards Codification. In addition, the ASU: (a) adds an example disclosure in Topic 275, Risks and Uncertainties, to illustrate one way that an entity that has not begun planned principal operations could provide information about the risks and uncertainties related to the company’s current activities; and (b) removes an exception provided to development stage entities in Topic 810, Consolidation, for determining whether an entity is a variable interest entity. The presentation and disclosure requirements in Topic 915 will no longer be required for the first annual period beginning after December 15, 2014. The revised consolidation standards are effective one year later, in annual periods beginning after December 15, 2015. Early adoption is permitted. The Company is evaluating the impact the adoption of ASU 2014-10 will have on its consolidated financial statements.

	On August 27, 2014, the FASB issued ASU 2014-15, which provides guidance on determining when and how reporting entities must disclose going-concern uncertainties in their financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date of issuance of the entity’s financial statements (or within one year after the date on which the financial statements are available to be issued, when applicable). Further, an entity must provide certain disclosures if there is “substantial doubt about the entity’s ability to continue as a going concern.” The ASU is effective for annual periods ending after December 15, 2016, and interim periods thereafter; early adoption is permitted. The Company is evaluating the impact the adoption of ASU 2014-15 will have on its consolidated financial statements.

Accrued_expenses_and_other_cur

Accrued expenses and other current liabilities	9 Months Ended
Accrued expenses and other current liabilities	Sep. 30, 2014
Accrued expenses and other current liabilities	'
	2. Accrued expenses and other current liabilities
	Accrued expenses and other current liabilities were comprised of the following (in thousands):


		September 30,		December 31,
		2014		2013
	Salary and related expenses	$	10,287	$	12,193
	Research and clinical trial costs		1,011		1,311
	Accrued interest		958		2,082
	Construction in progress		2,739		342
	Other		12,274		5,706

	Accrued expenses and other current liabilities	$	27,269	$	21,634

Accounting_for_stockbased_comp

Accounting for stock-based compensation	9 Months Ended
	Sep. 30, 2014
Accounting for stock-based compensation	'
	3. Accounting for stock-based compensation
	Total stock-based compensation expense recognized in the accompanying condensed consolidated statements of operations for the three and nine months ended September 30, 2014 and 2013 was as follows (in thousands):


		Three months ended					Nine months ended
		September 30,					September 30,
		2014			2013		2014		2013
	Stock-based compensation	$	(4,827	)	$	15,943	$	46,755	$	31,304

	During the three months ended March 31, 2014, the Company issued stock awards to employees primarily with a four-year vesting schedule. The grant date fair value of the 46,400 restricted stock units and 17,700 stock options issued were $296,000 and $81,000, respectively, with a grant date fair value per share of $6.39 and $4.58, respectively.
	During the three months ended June 30, 2014, the Company issued stock awards to employees primarily with a four-year vesting schedule as well as non-employee directors primarily with a three-year vesting schedule. The grant date fair value of the 158,600 restricted stock units and 252,600 stock options issued were $1.23 million and $1.32 million, respectively. The grant date fair value per share was $7.76 for restricted stock units, $5.31 for employee stock options and $5.22 for non-employee director stock options.
	On June 30, 2014, the Company modified certain performance grants to allow 124 employees to withhold in excess of the minimum statutory requirements for performance-based restricted stock units at the employee’s discretion through December 31, 2014. The modification resulted in the reclassification of these performance grants from equity awards to liability awards, which require re-measurement at the end of each reporting period through settlement. Consequently, as of June 30, 2014, the reclassification and re-measurement of these performance-based restricted stock units resulted in an increase in stock-based compensation expense of $35.9 million.
	During the three months ended September 30, 2014, the performance shares related to the modification settled. The performance grants were re-measured on their respective settlement dates, which resulted in a credit to stock compensation expense of $12.9 million. As of September 30, 2014, there were no remaining liability awards.
	During the three months ended September 30, 2014, the Company issued stock awards to employees primarily with a four-year vesting schedule. The grant date fair value of the 720,000 restricted stock units and 1,053,900 stock options issued were $5.1 million and $4.9 million, respectively, with a grant date fair value per share of $7.09 and $4.66, respectively.
	As of September 30, 2014, there was $10.3 million of unrecognized compensation cost related to options and $12.5 million of unrecognized compensation cost related to restricted stock units, which are expected to be recognized over the remaining weighted average vesting period of 3.0 years. The Company evaluates stock awards with performance conditions as to the probability that the performance conditions will be met and estimates the date at which the performance conditions will be met in order to properly recognize stock-based compensation expense over the requisite service period. As of September 30, 2014, there were no awards with milestones not considered probable of achievement.

Net_loss_per_common_share

Net loss per common share	9 Months Ended
Net loss per common share	Sep. 30, 2014
Net loss per common share	'
	4. Net loss per common share

	Basic net loss per share excludes dilution for potentially dilutive securities and is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period excluding the shares loaned to Bank of America, N.A. under a share lending arrangement (see Note 7 — Common and preferred stock). As of September 30, 2014, 9,000,000 shares of the Company’s common stock loaned to Bank of America pursuant to the terms of a share lending agreement as described in Note 7, were issued and are outstanding, and the holder of the borrowed shares has all the rights of a holder of the Company’s common stock. However, because the share borrower must return all borrowed shares to the Company (or, in certain circumstances, the cash value thereof), the borrowed shares are not considered outstanding for the purpose of computing and reporting basic or diluted earnings (loss) per share. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Potentially dilutive securities are excluded from the computation of diluted net loss per share for all of the periods presented in the accompanying condensed consolidated statements of operations because the reported net loss in each of these periods results in their inclusion being antidilutive. Antidilutive securities, which consist of stock options, restricted stock units, warrants, and shares that could be issued upon conversion of the senior convertible notes, that are not included in the diluted net loss per share calculation consisted of an aggregate of 47,820,744 shares and 133,944,425 shares as of September 30, 2014 and 2013, respectively, and exclude the 9,000,000 shares loaned under the share lending arrangement.

State_research_and_development

State research and development credit exchange receivable	9 Months Ended
State research and development credit exchange receivable	Sep. 30, 2014
State research and development credit exchange receivable	'
	5. State research and development credit exchange receivable
	The State of Connecticut provides certain companies with the opportunity to exchange certain research and development income tax credit carryforwards for cash in exchange for forgoing the carryforward of the research and development income tax credits. The program provides for an exchange of research and development income tax credits for cash equal to 65% of the value of corporation tax credit available for exchange. Current estimated amounts receivable under the program were $803,000 at September 30, 2014, and there was no current portion at December 31, 2013. Long-term estimated amounts receivable under the program were $260,000 and $298,000 at September 30, 2014 and December 31, 2013, respectively.

Property_and_equipment

Property and equipment	9 Months Ended
Property and equipment	Sep. 30, 2014
Property and equipment	'
	6. Property and equipment
	Property and equipment — net consisted of the following (dollar amounts in thousands):


		Estimated		September 30,			December 31,
		Useful		2014			2013
		Life
		(Years)
	Land		—	$	5,273		$	5,273
	Buildings		39-40		54,948			54,948
	Building improvements		May-40		114,131			114,099
	Machinery and equipment		15-Mar		82,068			82,189
	Furniture, fixtures and office equipment		10-May		5,087			5,046
	Computer equipment and software		3		11,335			11,289
	Leasehold improvements		4		17			17
	Construction in progress				36,214			14,756

					309,073			287,617
	Less accumulated depreciation and amortization				(118,150	)		(111,060	)

	Property and equipment — net			$	190,923		$	176,557

	Leasehold improvements are amortized over four years which is the shorter of the term of the lease or the service lives of the improvements.
	Depreciation and amortization expense related to property and equipment for the three and nine months ended September 30, 2014 and 2013 was as follows (in thousands):


		Three months ended					Nine months ended
		September 30,					September 30,
		2014		2013			2014			2013
	Depreciation and amortization expense	$	2,414	$	2,874		$	7,386		$	8,820

Common_and_preferred_stock

Common and preferred stock	9 Months Ended
Common and preferred stock	Sep. 30, 2014
Common and preferred stock	'

	7. Common and preferred stock

	The Company is authorized to issue 550,000,000 shares of common stock, par value $0.01 per share, and 10,000,000 shares of undesignated preferred stock, par value $0.01 per share, issuable in one or more series designated by the Company’s board of directors. No other class of capital stock is authorized. As of September 30, 2014 and December 31, 2013, 405,469,034 and 369,391,972 shares of common stock, respectively, were issued and outstanding and no shares of preferred stock were outstanding. Included in the common stock outstanding as of September 30, 2014 and December 31, 2013 are 9,000,000 shares of common stock loaned to Bank of America under a share lending agreement in connection with the offering of $100.0 million aggregate principal amount of 2015 notes (see Note 10 — Senior convertible notes). Bank of America is obligated to return the borrowed shares (or, in certain circumstances, the cash value thereof) to the Company on or about the 45th business day following the date as of which the entire principal amount of the 2015 notes ceases to be outstanding, subject to extension or acceleration in certain circumstances or early termination at Bank of America’s option. The Company did not receive any proceeds from the sale of the borrowed shares by Bank of America, but the Company did receive a nominal lending fee of $0.01 per share from Bank of America for the use of borrowed shares.

	On July 1, 2013, the Company entered into the Facility Agreement with Deerfield providing for the sale of up to $160.0 million of 2019 notes to Deerfield in four equal tranches of $40.0 million principal amount. On February 28, 2014, the Company amended the Facility Agreement to, among other things, allow Deerfield, subject to certain limitations, to convert up to an additional $60.0 million principal amount under the then-outstanding 2019 notes into the Company’s common stock after the effective date of the First Amendment. The Company also agreed to register for resale up to 12,000,000 shares of common stock issuable upon conversion of the outstanding 2019 notes, with a minimum conversion price of $5.00 per share unless the Company otherwise consents. The conversion price was determined by the average of the volume weighted average prices per share during the three trading days immediately preceding the election to convert. As of September 30, 2014, Deerfield had converted $100.0 million of 2019 notes into 18,616,304 shares of the Company’s common stock which resulted in total expense of $6.4 million for the nine months ended September 30, 2014 and $0.6 million for the twelve months ended December 31, 2013 for the difference between the principal amount of the notes converted and their carrying amount (see Note 11 – Facility Agreement). No additional principal amount of 2019 notes is convertible.

Commitments_and_contingencies

Commitments and contingencies	9 Months Ended
Commitments and contingencies	Sep. 30, 2014
Commitments and contingencies	'
	8. Commitments and contingencies
	Guarantees and Indemnifications — In the ordinary course of its business, the Company makes certain indemnities, commitments and guarantees under which it may be required to make payments in relation to certain transactions. The Company, as permitted under Delaware law and in accordance with its Bylaws, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that may enable it to recover a portion of any future amounts paid. The Company believes the fair value of these indemnification agreements is minimal. The Company has not recorded any liability for these indemnities in the accompanying condensed consolidated balance sheets. However, the Company accrues for losses for any known contingent liability, including those that may arise from indemnification provisions, when future payment is probable and the amount can be reasonably estimated.
	Litigation — The Company is subject to legal proceedings and claims which arise in the ordinary course of its business. As of the date hereof, the Company believes that the final disposition of such matters will not have a material adverse effect on the financial position, results of operations or cash flows of the Company. The Company maintains liability insurance coverage to protect the Company’s assets from losses arising out of or involving activities associated with ongoing and normal business operations. In accordance with ASC 450 Contingencies, the Company would record a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.
	Contingencies — In connection with the Facility Agreement, on July 1, 2013 the Company also entered into a Milestone Rights Purchase Agreement (the “Milestone Agreement”) with Deerfield Private Design Fund and Horizon Santé FLML SÁRL (collectively, the “Milestone Purchasers”), pursuant to which the Company sold the Milestone Purchasers certain rights (the “Milestone Rights”) to receive payments of up to $90.0 million upon the occurrence of specified strategic and sales milestones, including the first commercial sale of an AFREZZA product in the United States and the achievement of specified net sales figures (see Note 11 – Facility Agreement).

Relatedparty_arrangements

Related-party arrangements	9 Months Ended
Related-party arrangements	Sep. 30, 2014
Related-party arrangements	'

	9. Related-party arrangements

	In October 2007, the Company entered into a $350.0 million loan arrangement with its principal stockholder. The Loan Arrangement has been amended from time to time. On October 31, 2013, the promissory note underlying the Loan Arrangement was amended to, among other things, extend the maturity date of the loan to January 5, 2020, extend the date through which the Company can borrow under the Loan Arrangement to December 31, 2019, increase the aggregate borrowing amount under the Loan Arrangement from $350.0 million to $370.0 million and provide that repayments or cancellations of principal under the Loan Arrangement will not be available for reborrowing.



	As of September 30, 2014, the total principal amount outstanding under the Loan Arrangement was $49.5 million and the amount available for future borrowings was $30.1 million. Interest, at a fixed rate of 5.84%, is due and payable quarterly in arrears on the first day of each calendar quarter for the preceding quarter, or at such other time as the Company and The Mann Group mutually agree. All or any portion of accrued and unpaid interest that becomes due and payable may be paid-in-kind and capitalized as additional borrowings at any time upon mutual agreement of both parties and would be classified as non-current. As of September 30, 2014, the Company had accrued $2.8 million of interest in other liabilities related to the Loan Arrangement. The Mann Group can require the Company to prepay up to $200.0 million in advances that have been outstanding for at least 12 months (less approximately $105.0 million aggregate principal amount that has been cancelled in connection with two common stock purchase agreements). If The Mann Group exercises this right, the Company will have 90 days after The Mann Group provides written notice (or the number of days to maturity of the note if less than 90 days) to prepay such advances. However, pursuant to a letter agreement entered into in August 2010, The Mann Group has agreed to not require the Company to prepay amounts outstanding under the amended and restated promissory note if the prepayment would require the Company to use its working capital resources. In addition, The Mann Group entered into a subordination agreement with Deerfield pursuant to which The Mann Group agreed with Deerfield not to demand or accept any payment under the Loan Arrangement until the Company’s payment obligations to Deerfield under the Facility Agreement have been satisfied in full. Subject to the foregoing, in the event of a default under the Loan Arrangement, all unpaid principal and interest either becomes immediately due and payable or may be accelerated at The Mann Group’s option, and the interest rate will increase to the one-year LIBOR calculated on the date of the initial advance or in effect on the date of default, whichever is greater, plus 5% per annum. All borrowings under the Loan Arrangement are unsecured. The Loan Arrangement contains no financial covenants.

	During the nine months ended September 30, 2014, there were no additional borrowings under or amendments to the Loan Arrangement.

Senior_convertible_notes

Senior convertible notes	9 Months Ended
Senior convertible notes	Sep. 30, 2014
Senior convertible notes	'
	10. Senior convertible notes
	Senior convertible notes consisted of the following (in thousands):


		September 30,			December 31,
		2014			2013
	2015 notes
	Principal amount	$	100,000		$	100,000
	Unaccreted debt issuance expense		(880	)		(1,561	)

	Net carrying amount	$	99,120		$	98,439

	On August 18, 2010, the Company completed a Rule 144A offering of $100.0 million aggregate principal amount of 2015 notes. The 2015 notes are governed by the terms of an indenture dated as of August 24, 2010 (the “2015 Note Indenture”). The 2015 notes bear interest at the rate of 5.75% per year on the principal amount, payable in cash semi-annually in arrears on February 15 and August 15 of each year, beginning February 15, 2011. In connection with the 2015 notes, the Company had accrued interest of $1.0 million and $2.4 million as of September 30, 2014 and December 31, 2013, respectively. The 2015 notes are general, unsecured, senior obligations of the Company and effectively rank junior in right of payment to all of the Company’s secured debt, to the extent of the value of the assets securing such debt and to the debt and all other liabilities of the Company’s subsidiaries. The maturity date of the 2015 notes is August 15, 2015 and payment is due in full on that date for unconverted securities. Because the 2015 notes are due within twelve months, the Company reclassified the 2015 notes from a long term liability to a current liability at September 30, 2014. Holders of the 2015 notes may convert, at any time prior to the close of business on the business day immediately preceding the stated maturity date, any outstanding principal into shares of the Company’s common stock at an initial conversion rate of 147.0859 shares per $1,000 principal amount, which is equal to a conversion price of approximately $6.80 per share, subject to adjustment. Except in certain circumstances, if the Company undergoes a fundamental change: (1) the Company will pay a make-whole premium on the 2015 notes converted in connection with a fundamental change by increasing the conversion rate on such 2015 notes, which amount, if any, will be based on the Company’s common stock price and the effective date of the fundamental change, and (2) each holder of 2015 notes will have the option to require the Company to repurchase all or any portion of such holder’s 2015 notes at a repurchase price of 100% of the principal amount of the 2015 notes to be repurchased plus accrued and unpaid interest, if any. The Company may elect to redeem some or all of the 2015 notes if the closing stock price has equaled 150% of the conversion price for at least 20 of the 30 consecutive trading days ending on the trading day before the Company’s redemption notice. The redemption price will equal 100% of the principal amount of the 2015 notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date, plus a make-whole payment equal to the sum of the present values of the remaining scheduled interest payments through and including August 15, 2015 (other than interest accrued up to, but excluding, the redemption date). The Company will be obligated to make the make-whole payment on all the 2015 notes called for redemption and converted during the period from the date the Company mailed the notice of redemption to and including the redemption date. The Company may elect to make the make-whole payment in cash or shares of its common stock, subject to certain limitations. Under the terms of the 2015 Note Indenture, the conversion option can be net-share settled and the maximum number of shares that could be required to be delivered under the contract, including the make-whole shares, is fixed and less than the number of authorized and unissued shares less the maximum number of shares that could be required to be delivered during the contract period under other existing commitments. Applying the Company’s sequencing policy, the Company performed an analysis at the time of the offering of the 2015 notes and each reporting date since and has concluded that the number of available authorized shares at the time of the offering and each subsequent reporting date was sufficient to deliver the number of shares that could be required to be delivered during the contract period under existing commitments.
	The Company incurred approximately $4.2 million in issuance costs which are recorded as an offset to the 2015 notes in the accompanying condensed consolidated balance sheets. These costs are being accreted to interest expense using the effective interest method over the term of the 2015 notes.
	The 2015 notes provide that upon an acceleration of certain indebtedness, including the 2019 notes and the Tranche B notes described in Note 11, the holders may elect to accelerate the Company’s repayment obligations under the 2015 notes if such acceleration is not cured, waived, rescinded or annulled. There can be no assurance that the holders would not choose to exercise these rights in the event such events were to occur.
	Accretion of debt issuance expense in connection with the 2015 notes during the three and nine months ended September 30, 2014 and 2013 was as follows (in thousands):


		Three months ended						Nine months ended
		September 30,						September 30,
		2014			2013			2014		2013
	Accretion expense	$	231		$	216		$	681	$	637

Facility_Agreement

Facility Agreement	9 Months Ended
Facility Agreement	Sep. 30, 2014
Facility Agreement	'
	11. Facility Agreement

	The significant activity related to the Facility Agreement during the nine months ended September 30, 2014 consisted of the following (in thousands):




		September 30,
		2014
	Facility financing obligation
	Carrying value at December 31, 2013	$	102,300
	Principal converted to equity		(93,500	)
	Accretion of debt discount and debt issuance expense		7,507
	Adjustment to debt discount related to modification of the 2019 notes		2,921
	Tranche B principal amount		20,000
	Debt discount related to Tranche B purchase		(1,168	)
	Tranche 4 principal amount		40,000
	Debt discount related to Tranche 4 purchase		(5,435	)

	Net carrying value of facility financing obligation	$	72,625

	Commitment Asset
	Commitment asset balance at December 31,2013	$	5,157
	Tranche B commitment asset fair value		2,921
	Less commitment asset portion associated with the receipt of Tranche 4 and Tranche B notes		(6,325	)

	Commitment asset value included in other assets	$	1,753



	Accretion of debt issuance cost and debt discount in connection with the Facility Agreement during the three and nine months ended September 30, 2014 were as follows (in thousands):




		Three months ended			Nine months ended
		September 30, 2014			September 30, 2014
	Accretion expense- debt issuance cost	$	9		$	318
	Accretion expense- debt discount	$	306		$	7,189
	On July 1, 2013, the Company entered into the Facility Agreement providing for the sale of up to $160.0 million of 2019 notes to Deerfield in four equal tranches of $40.0 million principal amount. The 2019 notes accrue interest at a rate of 9.75% per annum until maturity in 2019 or their earlier repayment, repurchase, or conversion. As of September 30, 2014, Deerfield had purchased the four tranches of 2019 notes in the aggregate principal amount of $160.0 million.

	On February 28, 2014, the Company entered into the First Amendment, which modified the terms of the Facility Agreement to provide for the issuance of Tranche B notes to Deerfield. Pursuant to the terms of the First Amendment and the subsequent occurrence of certain events specified in the First Amendment, prior to December 30, 2014, the Company may request that Deerfield purchase up to $90.0 million aggregate principal amount of Tranche B notes. The Tranche B notes initially accrued interest at the rate of 9.75% per year on the outstanding principal amount, subject to reduction to 8.75% if the Company entered into a collaboration with a third party to commercialize AFREZZA. Pursuant to the terms of the First Amendment, the interest rate was subsequently reduced to 8.75% on September 23, 2014 following completion of the U.S. Federal Trade Commission’s review of the transactions contemplated by the Sanofi License Agreement under the Hart-Scott-Rodino Act and the completion of documentation related to the $175.0 million secured loan facility being provided to the Company. The interest on the outstanding principal amount of notes under the Facility Agreement is payable in cash quarterly in arrears on the last business day of March, June, September and December of each year. The Company is required to repay 25% of the original principal amount of any Tranche B notes on the third, fourth, fifth and sixth anniversaries of the applicable issue dates of such notes, provided that the entire outstanding principal amount of all Tranche B notes will become due and payable no later than December 31, 2019. The Tranche B notes can be prepaid without penalty or premium commencing two years after issuance thereof. On May 6, 2014, Deerfield purchased an aggregate principal amount of $20.0 million in Tranche B notes in accordance with the provisions of the Facility Agreement, as amended. On July 18, 2014, Deerfield purchased an aggregate principal amount of $40.0 million of the fourth and final tranche of 2019 notes (the “Tranche 4 notes”) in accordance with the provisions of the Facility Agreement, as amended, which contains a financial covenant that requires the Company’s cash and cash equivalents which include available borrowings under the Loan Arrangement on the last day of each fiscal quarter to not be less than $25.0 million.

	In addition, pursuant to the First Amendment, the outstanding first tranche of 2019 notes (the “Tranche 1 notes”) and third tranche of 2019 notes (the “Tranche 3 notes”) held by Deerfield were amended and restated to permit Deerfield to convert up to an additional $60.0 million principal amount under such 2019 notes into the Company’s common stock after the effective date of the First Amendment. The Company also agreed to register for resale up to 12,000,000 shares of the Company’s common stock issuable upon conversion of the outstanding 2019 notes, as amended and restated, as of the date of the First Amendment. In March 2014, Deerfield elected to convert the full $40.0 million of outstanding principal amount of the Tranche 3 notes and $12.5 million principal amount of the Tranche 1 notes. In April 2014, Deerfield elected to convert the remaining $7.5 million principal amount of the Tranche 1 notes.

	On August 11, 2014, the Company entered into a second amendment to the Facility Agreement to permit the incurrence of additional secured debt under the Sanofi Loan Facility.

	Milestone Rights

	In connection with the execution of the Facility Agreement, on July 1, 2013, the Company issued Milestone Rights to the Milestone Purchasers. The Milestone Rights provide the Milestone Purchasers certain rights to receive payments of up to $90.0 million upon the occurrence of specified strategic and sales milestones, including the first commercial sale of an AFREZZA product in the United States and the achievement of specified net sales figures. The payments due under the Milestone Rights are subject to pro rata reduction in the event of certain funding failures by Deerfield under the Facility Agreement.

	The Milestone Agreement includes customary representations and warranties and covenants by the Company, including restrictions on transfers of intellectual property related to AFREZZA. The Milestone Rights are subject to acceleration in the event the Company transfers its intellectual property related to AFREZZA in violation of the terms of the Milestone Agreement.

	The Milestone Rights were initially recorded as a short-term liability equal to $3.2 million included in accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheet and a long-term liability equal to $13.1 million included in other liabilities. As of September 30, 2014, the first milestone triggering event was achieved following the Company’s entry into the Sanofi License Agreement, which resulted in a $1.9 million incremental charge to interest expense due to the increase in carrying value of the liability to the required $5.0 million payment, which was paid to Deerfield subsequent to September 30, 2014 pursuant to the terms of the Milestone Agreement. As of September 30, 2014, the short-term portion of the liability had a balance of $9.2 million and the long-term portion of the liability had a balance of $8.9 million.



	Commitment Asset

	In connection with the issuance of the Tranche 1 notes and the Milestone Rights, the Company recorded a commitment asset (the “Commitment Asset”) on July 1, 2013. As a result of the First Amendment, the Company recorded an additional Tranche B notes commitment asset (the “Tranche B Commitment Asset”) with an estimated fair value equal to $2.9 million. The Commitment Asset remaining as of September 30, 2014 represented the right to receive up to $70.0 million of funding remaining under the Facility Agreement, as amended, from the sale of the Tranche B notes. The Commitment Asset is derecognized and recorded as a debt discount on the 2019 notes and Tranche B notes when issued and amortized using the effective interest rate method over the life of the respective notes. Prior to derecognition occurring, the Company monitors the Commitment Asset on an ongoing basis to determine whether an impairment indicator is present that would result in a full or partial write down of the Commitment Asset as a result of events that may lead to the subsequent tranches of notes not being issued. Based on the monitoring procedures performed through September 30, 2014, the Company did not identify any indicators of impairment.

	Amendment to the outstanding Tranche 1 notes and Tranche 3 notes

The amendment and restatement of the outstanding Tranche 1 notes and Tranche 3 notes, pursuant to the First Amendment, did not represent a troubled debt restructuring of the 2019 notes because the First Amendment did not result in Deerfield granting a concession to the Company. In addition, the First Amendment did not result in a substantial modification to the terms of the Tranche 1 notes and Tranche 3 notes.

The impact of the First Amendment to the Tranche 1 notes and Tranche 3 notes is being accounted for as a prospective yield adjustment. Specifically, the value of the Tranche B Commitment Asset was considered a fee received from the creditor as consideration for the First Amendment and is being amortized as an adjustment of interest expense over the remaining term of the Tranche 1 notes and Tranche 3 notes using the effective interest method. Further, the value of the Tranche B Commitment Asset, which decreased the amount of debt discount in the Tranche 1 notes and Tranche 3 notes, was allocated between the Tranche 1 notes and Tranche 3 notes in a manner that resulted in the Tranche 1 notes and Tranche 3 notes having a new effective interest rate of 11.63%.

Conversion Option

For accounting purposes, the Company evaluated the embedded conversion option in the 2019 notes as a redemption feature because the number of shares issuable upon conversion was based on the volume weighted average prices for specified periods prior to the conversion date (as opposed to being fixed). Accordingly, conversions by Deerfield were treated as redemptions of the 2019 notes, and, the Company analyzed whether the conversion option required bifurcation as an embedded redemption feature. As of September 30, 2014, Deerfield had converted $100.0 million of 2019 notes into 18,616,304 shares of the Company’s common stock and no additional principal amount of the 2019 notes is convertible.

Income_taxes

Income taxes	9 Months Ended
Income taxes	Sep. 30, 2014
Income taxes	'
	12. Income taxes
	As required by ASC 740 Income Taxes (“ASC 740”), management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets and concluded, in accordance with the applicable accounting standards, that net deferred tax assets should be fully reserved.
	ASC 740-10-25 Income Taxes Recognition clarifies the accounting and disclosure for uncertainty in tax positions, as defined. This guidance seeks to reduce the diversity in practice associated with certain aspects of the recognition and measurement related to accounting for income taxes. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded pursuant to this guidance. Tax years since 1993 remain subject to examination by the major tax jurisdictions in which the Company is subject to tax.

Fair_value_of_financial_instru

Fair value of financial instruments

9 Months Ended

Sep. 30, 2014

Fair value of financial instruments

13. Fair value of financial instruments

The Company applies various valuation approaches in determining the fair value of its financial assets and liabilities within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:

Level 1— Quoted prices for identical instruments in active markets.

Level 2— Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.

Level 3— Significant inputs to the valuation model are unobservable.

The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level input that is significant to the overall fair value measurement.

Cash and cash equivalents

Cash equivalents consist of highly liquid investments with original or remaining maturities of 90 days or less at the time of purchase, that are readily convertible into cash. As of September 30, 2014 and December 31, 2013, the Company held $172.5 million and $70.8 million, respectively, of cash and cash equivalents, consisting primarily of money market funds of $169.7 million and $67.7 million, respectively, and the remaining in non-interest bearing checking accounts. The carrying value approximates the fair value. The fair value of these money market funds was determined by using quoted prices for identical investments in an active market (Level 1 in the fair value hierarchy).

The following is a summary of the carrying values and estimated fair values of the 2015 notes and the facility financing obligation (i.e., the 2019 notes and Tranche B notes) (in millions):

September 30, 2014

December 31, 2013

Carrying

Estimated

Carrying

Estimated

value

fair value

value

fair value

2015 notes

99.1

113.9

98.4

102.2

Facility financing obligation

72.6

75.3

102.3

107

Senior Convertible Notes

The estimated fair value of the 2015 notes was calculated based on model-derived valuations whose inputs were observable, such as the Company’s stock price, and non-observable, such as the Company’s longer-term historical volatility, which was estimated to be 85% (Level 3 in the fair value hierarchy). As there is no current observable market for the 2015 notes, the Company determined the estimated fair value using a convertible bond valuation model within a lattice framework. The convertible bond valuation model combined expected cash outflows with market-based assumptions regarding risk-adjusted yields, stock price volatility and recent price quotes and trading information regarding Company issued debt instruments and shares of common stock into which the notes are convertible.

Facility Agreement

As discussed in Note 11 — Facility Agreement, in connection with the Facility Agreement, the Company issued 2019 notes and Milestone Rights and recorded the Commitment Asset on July 1, 2013. In addition, on February 28, 2014, the Company entered into the First Amendment, and recorded the Tranche B Commitment Asset, which represented the increase in borrowing capacity that the Company received as consideration for the modifications made to the Facility Agreement and the Tranche 1 notes and Tranche 3 notes. As there is no current observable market for the 2019 notes or Tranche B notes, the Company determined the estimated fair value using a bond valuation model based on a discounted cash flow methodology. The bond valuation model combined expected cash flows associated with principal repayment and interest based on the contractual terms of the debt agreement discounted to present value using a selected market discount rate of 12.7% at December 31, 2013 for the 2019 notes and a selected market discount rate of 11.9% at the inception of the Tranche B notes (Level 3 in the fair value hierarchy). On September 30, 2014, the market discount rate was recalculated at 12.4% for the Tranche 1 notes and the Tranche 4 notes and 11.9% for the Tranche B notes. The Tranche 2 and Tranche 3 notes were fully converted by the end of the first quarter of 2014.

The estimated fair value of the Milestone Rights was calculated using the income approach in which the cash flows associated with the specified contractual payments were adjusted for both the expected timing and the probability of achieving the milestones discounted to present value using a selected market discount rate (Level 3 in the fair value hierarchy). The expected timing and probability of achieving the milestones, starting in 2014, was developed with consideration given to both internal data, such as progress made to date and assessment of criteria required for achievement, and external data, such as market research studies. The discount rate (17.5%) was selected based on an estimation of required rate of returns for similar investment opportunities using available market data. As of September 30, 2014, the fair value of the Milestone Rights is estimated at $23.1 million.

The fair value of the Commitment Asset was estimated using the income approach by estimating the fair value of the future tranches using a market debt rate (12.0%) commensurate with the risk of the future tranches and the fair value of the cash expected to be received by the Company and assessing the probability of the commitments being funded in the future based on the operational hurdles required for funding being met (Level 3 in the fair value hierarchy). At September 30, 2014, as Deerfield had purchased all four tranches of 2019 notes in the aggregate principal amount of $160.0 million, the carrying value of the Commitment Asset was zero.

The fair value of the Tranche B Commitment Asset was estimated using a discounted cash flow analysis under the income approach. Specifically, the fair value was determined by estimating the fair value of the future tranche using a market yield (11.9%) commensurate with the risk of the future tranche and the fair value of the cash expected to be received by the Company and assessing the probability of the commitment being funded in the future based on the operational hurdles required for funding being met as well as consideration of alternative funding options (Level 3 in the fair value hierarchy). As of the date it was recorded, the Tranche B Commitment Asset was valued at $2.9 million.

On May 6, 2014, Deerfield purchased $20.0 million aggregate principal amount of Tranche B notes in accordance with the provisions of the Facility Agreement, as amended. Accordingly, the $1.2 million portion of the Commitment Asset associated with the $20.0 million purchased was derecognized and recorded as debt discount on the Tranche B notes. Consequently, the remaining carrying value of the Tranche B Commitment Asset was $1.8 million. As of September 30, 2014, because there have been no material changes to the established estimates, the carrying value of the Tranche B Commitment Asset approximates its respective estimated fair value.

There were no material re-measurements to fair value during the nine months ended September 30, 2014 and 2013 of financial assets and liabilities that are not measured at fair value on a recurring basis. There were no transfers of assets or liabilities between the fair value measurement levels during the nine months ended September 30, 2014 and 2013.

Collaboration_arrangement

Collaboration arrangement	9 Months Ended
Collaboration arrangement	Sep. 30, 2014
Collaboration arrangement	'

	14. Collaboration arrangement

	On August 11, 2014, the Company and Sanofi entered into a license and collaboration agreement, which became effective on September 23, 2014. Under the terms of the Sanofi License Agreement, the Company granted to Sanofi exclusive, worldwide licenses to certain of the Company’s patents, trademarks and know-how for the development and commercialization of AFREZZA. Under the terms of the Sanofi License Agreement, Sanofi has the exclusive right and responsibility to develop AFREZZA worldwide, subject to certain development activities that will be performed by the Company. Sanofi will also be obligated to use commercially reasonable efforts to file for, obtain and maintain marketing approvals for AFREZZA in certain major markets and countries. In addition, Sanofi will have exclusive, worldwide rights to commercialize AFREZZA and will be obligated to use commercially reasonable efforts to market, promote and commercialize AFREZZA in all countries in the world where regulatory approval for AFREZZA has been received. Pursuant to the terms of a supply agreement that the Company entered into with Sanofi concurrently with the Sanofi License Agreement, the Company will be responsible for the manufacture and supply to Sanofi of its requirements of AFREZZA.

	Under the Sanofi License Agreement, Sanofi paid the Company an up-front cash payment of $150.0 million in the third quarter of 2014. If certain manufacturing, regulatory and sales milestones are achieved, the Company will also be eligible to receive up to $775.0 million in milestone payments, of which $75.0 million relates to certain development and manufacturing milestone events, $50.0 million relates to the filing and completion of regulatory approvals and $650.0 million relates to the achievement of certain product sales milestones. In addition, worldwide profits and losses, which are determined based on the difference between the net sales of AFREZZA and the costs and expenses incurred by the Company and Sanofi that are specifically attributable or related to the development, improvement, regulatory filings, manufacturing, and commercialization of AFREZZA will be shared 65% by Sanofi and 35% by the Company. In accordance with the terms of the Sanofi License Agreement, profit and loss sharing will commence the first full calendar quarter subsequent to the execution date of the agreement.



	On September 23, 2014, the Company entered into the Sanofi Loan Facility, consisting of a senior secured revolving promissory note (the “Note”) and a guaranty and security agreement (the “Security Agreement”) with an affiliate of Sanofi which provides the Company with a secured loan facility of up to $175.0 million to fund the Company’s share of net losses under the Sanofi License Agreement.

	The obligations of the Company under the Sanofi Loan Facility are guaranteed by the Company’s wholly-owned subsidiary, MannKind LLC, and are secured by a first priority security interest in certain insulin inventory located in the United States and any contractual rights and obligations pursuant to which the Company purchases or has purchased such insulin, and a second priority security interest in the Company’s assets that secure the Company’s obligations under the Facility Agreement, as amended. In addition, the Company agreed to grant to Sanofi, as additional security for the obligations under the Sanofi Loan Facility, a first priority mortgage on the Company’s facility in Valencia, California, by December 22, 2014.

	Advances under the Sanofi Loan Facility bear interest at a rate of 8.5% per annum and are payable in-kind and compounded quarterly and added to the outstanding principal balance under the Sanofi Loan Facility. The Company is required to make mandatory prepayments on the outstanding loans under the Sanofi Loan Facility from its share of any Profits (as defined in the Sanofi License Agreement) under the Sanofi License Agreement within 30 days of receipt of its share of any such Profits. No advances may be made under the Sanofi Loan Agreement if Deerfield has commenced enforcement proceedings in connection with an event of default under the Facility Agreement.

	The outstanding principal of all loans under the Sanofi Loan Facility, if not prepaid, will become due and payable on September 23, 2024 unless accelerated pursuant to the terms of the Sanofi Loan Facility. Additionally, if the Company sells its Valencia facility, the Company is required to prepay the loans under the Sanofi Loan Facility in an amount equal to 100% of the net cash proceeds of the sale within five business days of receipt.

	The Sanofi Loan Facility includes customary representations, warranties and covenants by the Company, including restrictions on its ability to incur additional indebtedness, grant certain liens and make certain changes to its organizational documents. Events of default under the Sanofi Loan Facility include: the Company’s failure to timely make payments due under the Sanofi Loan Facility; inaccuracies in the Company’s representations and warranties to the noteholder; the Company’s failure to comply with any of its covenants under any of the Sanofi Loan Facility or certain other related security agreements and documents entered into in connection with the Sanofi Loan Facility, subject to a cure period with respect to most covenants; the Company’s insolvency or the occurrence of certain bankruptcy-related events; termination by Sanofi of the Sanofi License Agreement as a result of the Company’s breach of the Sanofi License Agreement; and the failure of any material provision under any of the Sanofi Loan Facility or certain other related security agreements and documents entered into in connection with the Sanofi Loan Facility to remain in full force and effect. If one or more events of default occurs and is continuing, Sanofi may terminate its obligation to make advances under the Sanofi Loan Facility, and, if certain specified events of default (including the Company’s failure to timely make payments due under the Sanofi Loan Facility; the Company’s failure to comply with the negative covenants under the Sanofi Loan Facility limiting the Company’s ability to incur additional indebtedness or grant certain liens; the Company’s insolvency or the occurrence of certain bankruptcy-related events; termination by Sanofi of the Sanofi License Agreement as a result of the Company’s breach of the non-compete provisions of the Sanofi License Agreement; or the failure of any material provision under any of the Sanofi Loan Facility or certain other related security agreements and documents entered into in connection with the Sanofi Loan Facility to remain in full force and effect) occur and are continuing, the noteholder may accelerate all of the Company’s repayment obligations under the Sanofi Loan Facility and otherwise exercise any of its remedies as a secured creditor. There can be no assurance that the noteholder would not choose to exercise these rights in the event such events were to occur.

	The Company analyzed the up-front cash payment of $150.0 million under the provisions of ASC 605, Revenue Recognition, to determine whether the up-front cash payment, or a portion thereof, could be recognized as revenue. ASC 605 provides that revenue is recognized when there is persuasive evidence that an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable and collection is reasonably assured. In addition, revenue arrangements with multiple elements are divided into separate units of accounting if certain criteria are met, including whether the delivered element has stand-alone value to the customer. When deliverables are separable, consideration received is allocated to the separate units of accounting based on the relative selling price of each deliverable and the appropriate revenue recognition principles are applied to each unit.

	The assessment of multiple element arrangements requires judgment in order to determine the appropriate units of accounting and the points in time that, or periods over which, revenue should be recognized. Under the terms of the Sanofi License Agreement, the Company determined that the arrangement contained significant deliverables including (i) licenses to develop and commercialize AFREZZA and to use the Company’s trademarks, (ii) transfer of know-how, (iii) development activities, and (iv) manufacture and supply services for AFREZZA. Due to the proprietary nature of the manufacturing services being provided by the Company, the Company determined that all of the significant deliverables should be combined into a single unit of accounting. The Company believes that the manufacturing services are proprietary due to the fact that over the past twelve years, the Company has developed proprietary knowledge and patented equipment and tools that are used in the manufacturing process of AFREZZA. Due to the complexities of particle formulation and the specialized knowledge and equipment needed to handle the AFREZZA powder, neither Sanofi nor any third-party contract manufacturing organization currently possesses the capability of manufacturing AFREZZA.



	In order for revenue to be recognized, the seller’s price to the buyer must be fixed and determinable and thus not subject to refund or adjustment. Given that as of September 30, 2014, the Company did not have the ability to estimate the amount of costs that would potentially be incurred under the loss share provision related to the Sanofi License Agreement, the Company believes this requirement for revenue recognition is not met.

	As such, the Company did not recognize any revenue pursuant to the Sanofi License Agreement for the three months ended September 30, 2014. The Company recorded the $150.0 million up-front payment as a deferred up-front payment from the Sanofi License Agreement.

Description_of_business_and_ba1

Description of business and basis of presentation (Policies)	9 Months Ended
	Sep. 30, 2014
Business	'
Business	Business — The Company is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases such as diabetes. The Company’s lead product, AFREZZA (insulin human) inhalation powder, is a rapid-acting inhaled insulin that was approved by the U.S. Food and Drug Administration (“FDA”) on June 27, 2014 to improve glycemic control in adult patients with diabetes.
Basis of Presentation	'

	Basis of Presentation — The Company is considered to be in the development stage as its primary activities since incorporation have been establishing its facilities, recruiting personnel, conducting research and development, business development, business and financial planning, and raising capital. It is costly to develop therapeutic products and conduct clinical studies for these products. From its inception through September 30, 2014, the Company had accumulated net losses of $2.5 billion, which include cumulative negative cash flow from operations of $1.7 billion and a goodwill impairment charge of $151.4 million.

	On August 11, 2014, the Company entered into a license and collaboration agreement (the “Sanofi License Agreement”) with Sanofi-Aventis Deutschland GmbH (which subsequently assigned its rights and obligations under the agreement to Sanofi-Aventis U.S. LLC (“Sanofi”)), pursuant to which Sanofi will be responsible for global commercial, regulatory and development activities for AFREZZA. Under the Sanofi License Agreement, the Company received a $150.0 million up-front fee and may earn up to an aggregate of $775.0 million upon the achievement of certain development, manufacturing, regulatory and sales milestones. Worldwide profits and losses with respect to AFREZZA will be shared 65% by Sanofi and 35% by the Company. Pursuant to a supply agreement, the Company will manufacture AFREZZA at its manufacturing facility in Danbury, Connecticut to supply Sanofi’s demand for the product. The Sanofi License Agreement became effective on September 23, 2014 following completion of the U.S. Federal Trade Commission’s review of the transactions contemplated by the Sanofi License Agreement under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder (the “Hart-Scott-Rodino Act”) and the completion of documentation related to the $175.0 million secured loan facility being provided to the Company by an affiliate of Sanofi (the “Sanofi Loan Facility”) to fund the Company’s share of net losses under the Sanofi License Agreement.

	At September 30, 2014, the Company’s capital resources consisted of cash and cash equivalents of $172.5 million. The Company expects to continue to incur significant expenditures to support commercial launch of AFREZZA and the development of other product candidates as contemplated under the Sanofi License Agreement. In addition, the Company’s 5.75% Senior Convertible Notes due 2015 (the “2015 notes”) in the aggregate principal amount of $100.0 million have a maturity date of August 15, 2015, and payment on the outstanding amount is due in full on that date (see Note 10 – Senior convertible notes).



	The Company may need to raise additional capital, whether through the sale of equity or debt securities, additional strategic business collaborations, the establishment of other funding facilities, licensing arrangements, asset sales or other means. Additional funding sources that are, or in certain circumstances may be available to the Company, include approximately $30.1 million principal amount of available borrowings under its loan arrangement ( the “Loan Arrangement”) with The Mann Group LLC (“The Mann Group”) (see note 9 – Related-party arrangements), potential proceeds from the exercise of warrants issued in its February 2012 public offering of approximately $20 million, the Company’s at-the-market issuance sales agreements which allow the Company to sell up to $50 million in common stock, and pursuant to the facility agreement (the “Facility Agreement”) with Deerfield Private Design Fund II, L.P. (“Deerfield Private Design Fund”) and Deerfield Private Design International II, L.P. (collectively, “Deerfield”) and the First Amendment to Facility Agreement and Registration Rights Agreement (the “First Amendment”) additional sales of an additional tranche of notes (the “Tranche B notes”) of up to $70 million which must be purchased prior to December 30, 2014 (see Note 11 – Facility Agreement).

	Although we believe that our existing cash and cash equivalents and available debt financing will be sufficient to finance our operational cash needs through at least the next twelve months, should our results not meet our current operating plan, it could negatively impact our liquidity and we may need to raise additional capital or seek additional financing sources as discussed above. There can be no assurance that we would be able to raise such additional financing or additional capital on acceptable terms, or at all, and if we are not able to raise adequate additional financing or capital to continue to fund our ongoing operations, we will need to defer, reduce or eliminate significant planned expenditures or significantly curtail our operations, and there may be substantial doubt about our ability to continue as a going concern.
Prepaid expenses and other current assets	'
	Prepaid expenses and other current assets — Prepaid expenses and other current assets primarily consist of prepaid expenses for goods and services to be received. As of September 30, 2014, prepaid and other current assets had a balance of $20.3 million, mainly comprised of a $15.0 million prepayment for 2015 quantities of insulin, prepaid insurance, and prepaid clinical trial expenses.
	On July 31, 2014, the Company entered into a Supply Agreement (the “Supply Agreement”) with Amphastar France Pharmaceuticals S.A.S., a French corporation (“Amphastar”), pursuant to which Amphastar will manufacture for and supply to the Company certain quantities of recombinant human insulin for use in AFREZZA. Under the terms of the Supply Agreement, Amphastar will be responsible for manufacturing the insulin in accordance with the Company’s specifications and agreed-upon quality standards. The Company has agreed to purchase annual minimum quantities of insulin under the Supply Agreement of an aggregate of approximately €120.1 million in calendar years 2015 through 2019. The Company may request to purchase additional quantities of insulin over such annual minimum quantities. As part of the Supply Agreement, the Company paid a $15.0 million deposit to Amphastar as prepayment for 2015 quantities of insulin.
	Unless earlier terminated, the term of the Supply Agreement expires on December 31, 2019 and can be renewed for additional, successive two year terms upon 12 months’ written notice, given prior to the end of the initial term or any additional two year term. The Company and Amphastar each have normal and customary termination rights, including termination for material breach that is not cured within a specific time frame or in the event of liquidation, bankruptcy or insolvency of the other party. In addition, the Company may terminate the Supply Agreement upon two years’ prior written notice to Amphastar without cause or upon 30 days’ prior written notice to Amphastar if a controlling regulatory authority withdraws approval for AFREZZA, provided, however, in the event of a termination pursuant to either of the latter two scenarios, the provisions of the Supply Agreement require the Company to pay the full amount of all unpaid purchase commitments due over the initial term within 60 calendar days of the effective date of such termination.
Sale of intellectual property	'
Sale of intellectual property	Sale of intellectual property — On July 18, 2014, the Company entered into an assignment agreement with a third party whereby the third party acquired all proprietary rights, technology and know-how that related to a small molecule inhibitor compound and all pre-clinical data and results related thereto. Under the terms of the assignment agreement, the Company received total consideration of $9.3 million, which was offset by $1.4 million of expense associated with the sale of the intellectual property related to oncology.
Fair Value of Financial Instruments	'
Fair Value of Financial Instruments	Fair Value of Financial Instruments — The carrying amounts reported in the accompanying financial statements for cash and cash equivalents, accounts payable and accrued liabilities approximate their fair value due to their relatively short maturities. The fair value of the cash equivalents, note payable to related party, senior convertible notes, and the elements of the Facility Agreement are discussed in Note 13, “Fair value of financial instruments.”
Recently Issued Accounting Standards	'
	Recently Issued Accounting Standards — In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force). The amendments in this ASU provide guidance on the financial statements presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. An unrecognized tax benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward with certain exceptions, in which case such an unrecognized tax benefit should be presented in the financial statements as a liability. The amendments in this ASU do not require new recurring disclosures. The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The adoption of the new requirement did not have a significant impact on the Company’s consolidated financial statements.
	In May 2014, a new standard was issued related to revenue recognition, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The new standard will replace most of the existing revenue recognition standards in U.S. GAAP when it becomes effective on January 1, 2017. Early adoption is not permitted. The new standard allows for either “full retrospective” adoption, whereby the new standard is applied to each prior reporting period presented or “modified retrospective” adoption, whereby the new standard is only applied to the most current period presented with the cumulative effect of the change recognized at the date of the initial application. The Company is assessing the potential impact of the new standard on its consolidated statements of financial position and results of operations and comprehensive income (loss) and has not yet selected a transition method.
	In June 2014, the FASB issued ASU No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. The amendments in this ASU remove all incremental financial reporting requirements from GAAP for development stage entities, including the removal of Topic 915, Development Stage Entities, from the FASB Accounting Standards Codification. In addition, the ASU: (a) adds an example disclosure in Topic 275, Risks and Uncertainties, to illustrate one way that an entity that has not begun planned principal operations could provide information about the risks and uncertainties related to the company’s current activities; and (b) removes an exception provided to development stage entities in Topic 810, Consolidation, for determining whether an entity is a variable interest entity. The presentation and disclosure requirements in Topic 915 will no longer be required for the first annual period beginning after December 15, 2014. The revised consolidation standards are effective one year later, in annual periods beginning after December 15, 2015. Early adoption is permitted. The Company is evaluating the impact the adoption of ASU 2014-10 will have on its consolidated financial statements.
	On August 27, 2014, the FASB issued ASU 2014-15, which provides guidance on determining when and how reporting entities must disclose going-concern uncertainties in their financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date of issuance of the entity’s financial statements (or within one year after the date on which the financial statements are available to be issued, when applicable). Further, an entity must provide certain disclosures if there is “substantial doubt about the entity’s ability to continue as a going concern.” The ASU is effective for annual periods ending after December 15, 2016, and interim periods thereafter; early adoption is permitted. The Company is evaluating the impact the adoption of ASU 2014-15 will have on its consolidated financial statements.

Accrued_expenses_and_other_cur1

Accrued expenses and other current liabilities (Tables)	9 Months Ended
Accrued expenses and other current liabilities (Tables)	Sep. 30, 2014
Accrued Expenses and Other Current Liabilities	'
	Accrued expenses and other current liabilities were comprised of the following (in thousands):


		September 30,		December 31,
		2014		2013
	Salary and related expenses	$	10,287	$	12,193
	Research and clinical trial costs		1,011		1,311
	Accrued interest		958		2,082
	Construction in progress		2,739		342
	Other		12,274		5,706

	Accrued expenses and other current liabilities	$	27,269	$	21,634

Accounting_for_stockbased_comp1

Accounting for stock-based compensation (Tables)	9 Months Ended
Accounting for stock-based compensation (Tables)	Sep. 30, 2014
Stock-Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations	'
	Total stock-based compensation expense recognized in the accompanying condensed consolidated statements of operations for the three and nine months ended September 30, 2014 and 2013 was as follows (in thousands):


		Three months ended					Nine months ended
		September 30,					September 30,
		2014			2013		2014		2013
	Stock-based compensation	$	(4,827	)	$	15,943	$	46,755	$	31,304

Property_and_equipment_Tables

Property and equipment (Tables)	9 Months Ended
Property and equipment (Tables)	Sep. 30, 2014
Property and Equipment	'
	Property and equipment — net consisted of the following (dollar amounts in thousands):


		Estimated		September 30,			December 31,
		Useful		2014			2013
		Life
		(Years)
	Land		—	$	5,273		$	5,273
	Buildings		39-40		54,948			54,948
	Building improvements		May-40		114,131			114,099
	Machinery and equipment		15-Mar		82,068			82,189
	Furniture, fixtures and office equipment		10-May		5,087			5,046
	Computer equipment and software		3		11,335			11,289
	Leasehold improvements		4		17			17
	Construction in progress				36,214			14,756

					309,073			287,617
	Less accumulated depreciation and amortization				(118,150	)		(111,060	)

	Property and equipment — net			$	190,923		$	176,557

Depreciation and Amortization Expense	'
	Depreciation and amortization expense related to property and equipment for the three and nine months ended September 30, 2014 and 2013 was as follows (in thousands):


		Three months ended					Nine months ended
		September 30,					September 30,
		2014		2013			2014			2013
	Depreciation and amortization expense	$	2,414	$	2,874		$	7,386		$	8,820

Senior_convertible_notes_Table

Senior convertible notes (Tables)	9 Months Ended
Senior convertible notes (Tables)	Sep. 30, 2014
Summary of Senior Convertible Notes	'
	Senior convertible notes consisted of the following (in thousands):


		September 30,			December 31,
		2014			2013
	2015 notes
	Principal amount	$	100,000		$	100,000
	Unaccreted debt issuance expense		(880	)		(1,561	)

	Net carrying amount	$	99,120		$	98,439

Accretion of Debt Issuance Expense	'
	Accretion of debt issuance expense in connection with the 2015 notes during the three and nine months ended September 30, 2014 and 2013 was as follows (in thousands):


		Three months ended						Nine months ended
		September 30,						September 30,
		2014			2013			2014		2013
	Accretion expense	$	231		$	216		$	681	$	637

Facility_Agreement_Tables

Facility Agreement (Tables)	9 Months Ended
Facility Agreement (Tables)	Sep. 30, 2014
Components of Facility Financing Agreement	'
	The significant activity related to the Facility Agreement during the nine months ended September 30, 2014 consisted of the following (in thousands):


		September 30,
		2014
	Facility financing obligation
	Carrying value at December 31, 2013	$	102,300
	Principal converted to equity		(93,500	)
	Accretion of debt discount and debt issuance expense		7,507
	Adjustment to debt discount related to modification of the 2019 notes		2,921
	Tranche B principal amount		20,000
	Debt discount related to Tranche B purchase		(1,168	)
	Tranche 4 principal amount		40,000
	Debt discount related to Tranche 4 purchase		(5,435	)

	Net carrying value of facility financing obligation	$	72,625

	Commitment Asset
	Commitment asset balance at December 31,2013	$	5,157
	Tranche B commitment asset fair value		2,921
	Less commitment asset portion associated with the receipt of Tranche 4 and Tranche B notes		(6,325	)

	Commitment asset value included in other assets	$	1,753

Accretion of Debt Issuance Cost and Debt Discount	'
	Accretion of debt issuance cost and debt discount in connection with the Facility Agreement during the three and nine months ended September 30, 2014 were as follows (in thousands):


		Three months ended			Nine months ended
		September 30, 2014			September 30, 2014
	Accretion expense- debt issuance cost	$	9		$	318
	Accretion expense- debt discount	$	306		$	7,189

Fair_value_of_financial_instru1

Fair value of financial instruments (Tables)	9 Months Ended
	Sep. 30, 2014
Summary of Carrying Values and Estimated Fair Values of Notes and Facility Financing Obligation	'
	The following is a summary of the carrying values and estimated fair values of the 2015 notes and the facility financing obligation (i.e., the 2019 notes and Tranche B notes) (in millions):


		September 30, 2014				December 31, 2013
		Carrying		Estimated		Carrying		Estimated
		value		fair value		value		fair value
	2015 notes	$	99.1	$	113.9	$	98.4	$	102.2
	Facility financing obligation	$	72.6	$	75.3	$	102.3	$	107

Recovered_Sheet1

Description of Business and Basis of Presentation - Additional Information (Detail)

0 Months Ended

9 Months Ended

283 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

Jul. 18, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Jul. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Aug. 11, 2014

Sep. 30, 2014

Sep. 23, 2014

Aug. 11, 2014

Sep. 30, 2014

Dec. 31, 2013

Aug. 18, 2010

Feb. 28, 2014

Sep. 30, 2014

Sep. 23, 2014

Feb. 28, 2014

USD ($)

EUR (€)

USD ($)

License and Collaboration Agreement with Sanofi

Maximum

Senior convertible notes due August 15, 2015

Senior convertible notes due December 31, 2019

USD ($)

Second Amendment Facility Agreement

Sanofi-Aventis Deutschland GmbH

ATM Agreements

USD ($)

Deerfield

USD ($)

Tranche B notes

USD ($)

Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]

Deficit accumulated during the development stage

$2,458,343,000

$2,296,402,000

Goodwill impairment

151,428,000

Cash flow from operation since inception

1,700,000,000

Cash and cash equivalents

172,465,000

93,803,000

172,465,000

70,790,000

61,840,000

Debt facility principal amount

100,000,000

90,000,000

Senior notes, effective interest rate

8.50%

5.75%

8.75%

9.75%

Debt instrument maturity date

15-Aug-15

31-Dec-19

Available borrowings under loan agreement

30,100,000

Potential proceeds from the exercise of warrants from February 2012 public offering

20,000,000

Offering price of common stock under agreement

50,000,000

Additional sales of notes

40,000,000

79,500,000

159,500,000

70,000,000

Up-front fee

150,000,000

Potential milestone payment

775,000,000

Profits and losses sharing percentage

35.00%

65.00%

Maximum secured loan facility

175,000,000

Prepaid expenses and other current assets

20,253,000

5,485,000

Prepayment of prepaid insurance, and prepaid clinical trial expenses

15,000,000

Remaining minimum amount committed in calendar years 2015 through 2019

120,100,000

Supply Agreement expiration period

31-Dec-19

Supply Agreement renewal period

'2 years

Consideration received

9,300,000

Offset expense associated with intellectual property

$1,400,000

Recovered_Sheet2

Accrued Expenses and Other Current Liabilities (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Accrued Expenses and Other Current Liabilities [Line Items]	'	'
Salary and related expenses	$10,287	$12,193
Research and clinical trial costs	1,011	1,311
Accrued interest	958	2,082
Construction in progress	2,739	342
Other	12,274	5,706
Accrued expenses and other current liabilities	$27,269	$21,634

StockBased_Compensation_Expens

Stock-Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation	($4,827)	$15,943	$46,755	$31,304

Accounting_for_Stock_Based_Com

Accounting for Stock- Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended			6 Months Ended	9 Months Ended
	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2014	Sep. 30, 2014
	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Employee	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Number of restricted stock units issued	720,000	158,600	46,400	'	'
Number of stock options issued	1,053,900	252,600	17,700	'	'
Number of employees under modified performance grants	'	'	'	124	'
Increase in stock-based compensation expenses	'	'	'	$35,900,000	'
Credit to stock compensation expense	12,900,000	'	'	'	'
Remaining liability awards	0	'	'	'	0
Weighted average vesting period for unrecognized compensation cost	'	'	'	'	'3 years
Stock Options	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Share based payment award , vesting period	'4 years	'4 years	'4 years	'	'
Fair value of the stock options granted , value	4,900,000	1,320,000	81,000	'	'
Weighted average grant date fair value of the stock options granted	$4.66	5.31	4.58	'	'
Unrecognized compensation cost related to non vested stock options	10,300,000	'	'	'	10,300,000
Restricted Stock Units (RSUs)	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Fair value of Restricted stock options granted , value	5,100,000	1,230,000	296,000	'	'
Weighted average grant date fair value of the stock options granted	$7.09	'	6.39	'	'
Weighted average grant date fair value of restricted stock units	'	7.76	'	'	'
Unrecognized compensation cost related to non vested stock options	12,500,000	'	'	'	12,500,000
Non Employee Director Stock Options	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Share based payment award , vesting period	'	'3 years	'	'	'
Weighted average grant date fair value of the stock options granted	'	5.22	'	'	'
Performance Based Stock Options	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Unrecognized compensation cost related to non vested stock options	0	'	'	'	0
Performance Based Restricted Stock Units	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Unrecognized compensation cost related to non vested stock options	$0	'	'	'	$0

Net_Loss_per_Common_Share_Addi

Net Loss per Common Share - Additional Information (Detail)	9 Months Ended
Net Loss per Common Share - Additional Information (Detail)	Sep. 30, 2014	Sep. 30, 2013
Net Income Loss Per Common Share [Line Items]	'	'
Companies common stock share outstanding	9,000,000	'
Antidilutive securities	47,820,744	133,944,425
Shares loaned under the share lending arrangement	9,000,000	9,000,000

Recovered_Sheet3

State Research and Development Credit Exchange Receivable - Additional Information (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Accounts and Other Receivables [Line Items]	'	'
Percentage of credit exchange receivable	65.00%	'
Estimated amounts receivable under program, Current	$803,000	$0
Estimated amounts receivable under program, Long-term	$260,000	$298,000

Property_and_Equipment_Detail

Property and Equipment (Detail) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Property and equipment - gross	$309,073	$287,617
Less accumulated depreciation and amortization	-118,150	-111,060
Property and equipment - net	190,923	176,557
Land	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment - gross	5,273	5,273
Buildings	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment - gross	54,948	54,948
Buildings \| Minimum	'	'
Property, Plant and Equipment [Line Items]	'	'
Estimated Useful Life (Years)	'39 years	'
Buildings \| Maximum	'	'
Property, Plant and Equipment [Line Items]	'	'
Estimated Useful Life (Years)	'40 years	'
Building Improvements	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment - gross	114,131	114,099
Building Improvements \| Minimum	'	'
Property, Plant and Equipment [Line Items]	'	'
Estimated Useful Life (Years)	'5 years	'
Building Improvements \| Maximum	'	'
Property, Plant and Equipment [Line Items]	'	'
Estimated Useful Life (Years)	'40 years	'
Machinery and Equipment	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment - gross	82,068	82,189
Machinery and Equipment \| Minimum	'	'
Property, Plant and Equipment [Line Items]	'	'
Estimated Useful Life (Years)	'3 years	'
Machinery and Equipment \| Maximum	'	'
Property, Plant and Equipment [Line Items]	'	'
Estimated Useful Life (Years)	'15 years	'
Furniture, fixtures and office equipment	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment - gross	5,087	5,046
Furniture, fixtures and office equipment \| Minimum	'	'
Property, Plant and Equipment [Line Items]	'	'
Estimated Useful Life (Years)	'5 years	'
Furniture, fixtures and office equipment \| Maximum	'	'
Property, Plant and Equipment [Line Items]	'	'
Estimated Useful Life (Years)	'10 years	'
Computer Equipment and Software	'	'
Property, Plant and Equipment [Line Items]	'	'
Estimated Useful Life (Years)	'3 years	'
Property and equipment - gross	11,335	11,289
Leasehold Improvements	'	'
Property, Plant and Equipment [Line Items]	'	'
Estimated Useful Life (Years)	'4 years	'
Property and equipment - gross	17	17
Construction in Progress	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment - gross	$36,214	$14,756

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail)	9 Months Ended
Property and Equipment - Additional Information (Detail)	Sep. 30, 2014
Depreciation and Other Amortization Expenses [Line Items]	'
Amortization period of lease hold improvements	'4 years

Depreciation_and_Amortization_

Depreciation and Amortization Expense (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Property, Plant and Equipment [Line Items]	'	'	'	'
Depreciation and amortization expense	$2,414	$2,874	$7,386	$8,820

Common_and_Preferred_Stock_Add

Common and Preferred Stock - Additional Information (Detail) (USD $)	9 Months Ended	283 Months Ended					9 Months Ended	12 Months Ended		0 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013	Aug. 18, 2010	Sep. 30, 2014	Dec. 31, 2013	Feb. 28, 2014	Jul. 01, 2013	Jul. 01, 2013
				Senior convertible notes due August 15, 2015	Senior convertible notes due August 15, 2015	Senior convertible notes due August 15, 2015	Deerfield	Deerfield	Deerfield	Deerfield	Deerfield
							Senior convertible notes due December 31, 2019	Senior convertible notes due December 31, 2019	Senior convertible notes due December 31, 2019	Senior convertible notes due December 31, 2019	Senior convertible notes due December 31, 2019
										Notes Issued in Four Equal Tranches	Notes Issued in Four Equal Tranches
										Tranche
Class of Stock [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Common stock, shares authorized	550,000,000	550,000,000	550,000,000	'	'	'	'	'	'	'	'
Common stock, par value	$0.01	$0.01	$0.01	'	'	'	'	'	'	'	'
Undesignated preferred stock, shares authorized	10,000,000	10,000,000	'	'	'	'	'	'	'	'	'
Undesignated preferred stock, par value	$0.01	$0.01	$0.01	'	'	'	'	'	'	'	'
Common stock, shares issued	405,469,034	405,469,034	369,391,972	'	'	'	'	'	'	'	'
Common stock, shares outstanding	405,469,034	405,469,034	369,391,972	'	'	'	'	'	'	'	'
Common stock loaned under share lending agreement, shares	9,000,000	9,000,000	9,000,000	'	'	'	'	'	'	'	'
Undesignated preferred stock, shares outstanding	0	0	0	'	'	'	'	'	'	'	'
Principal amount	'	'	'	$100,000,000	$100,000,000	$100,000,000	'	'	'	'	$160,000,000
Nominal lending fee	$0.01	'	'	'	'	'	'	'	'	'	'
Maximum sales amount under the agreement	'	'	'	'	'	'	'	'	'	'	160,000,000
Number of equal tranches	'	'	'	'	'	'	'	'	'	4	'
Debt facility periodic principal amount	'	'	'	'	'	'	'	'	'	'	40,000,000
Aggregate principal amount of convertible notes	'	'	'	'	'	'	0	'	60,000,000	'	'
Common shares issuable upon conversion	'	'	'	'	'	'	18,616,304	'	12,000,000	'	'
Conversion price of shares	'	'	'	'	'	$6.80	'	'	$5	'	'
Amount of common shares issued upon conversion	93,500,000	100,000,000	'	'	'	'	100,000,000	'	'	'	'
Loss on debt conversion	'	'	'	'	'	'	$6,400,000	$600,000	'	'	'

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (Deerfield, Milestone Rights Liability, Maximum, USD $)	Jul. 01, 2013
In Millions, unless otherwise specified	Jul. 01, 2013
Deerfield \| Milestone Rights Liability \| Maximum	'
Commitments and Contingencies [Line Items]	'
Contingent liability for milestone payments	$90

RelatedParty_Arrangements_Addi

Related-Party Arrangements - Additional Information (Detail) (USD $)	Sep. 30, 2014	Oct. 31, 2013	Oct. 31, 2007	Oct. 31, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
		Principal stockholder	Principal stockholder	Principal stockholder	Principal stockholder	Principal stockholder	Principal stockholder	Related Party Debt	Related Party Debt
				Amended Agreement	Loan Arrangement	Loan Arrangement	Loan Arrangement	Letter Agreement	Letter Agreement
						Maximum	Minimum		LIBOR
Related Party Transaction [Line Items]	'	'	'	'	'	'	'	'	'
Loan agreement with related party	'	$370,000,000	$350,000,000	'	'	'	'	'	'
Promissory note maturity date	'	'	'	5-Jan-20	'	'	'	'	'
Principal amount outstanding under credit facility	'	'	'	'	49,500,000	'	'	'	'
Amount available for future borrowings	30,100,000	'	'	'	30,100,000	'	'	'	'
Fixed borrowing rate	'	'	'	'	5.84%	'	'	'	'
Interest payable	'	'	'	'	2,800,000	'	'	'	'
Amount prepaid for cancellation of indebtedness	'	'	'	'	'	200,000,000	'	'	'
Number of months advances outstanding	'	'	'	'	'	'	'12 months	'	'
Related party transaction prepayment period	'	'	'	'	'90 days	'	'	'	'
Aggregate principal amount cancelled	'	'	'	'	105,000,000	'	'	'	'
Interest rate (LIBOR)	'	'	'	'	'	'	'	'	5.00%
Description of variable rate interest	'	'	'	'	'	'	'	'The interest rate will increase to the one-year LIBOR calculated on the date of the initial advance or in effect on the date of default, whichever is greater, plus 5% per annum.	'
Additional borrowings	$0	'	'	'	'	'	'	'	'

Summary_of_Senior_Convertible_

Summary of Senior Convertible Notes (Detail) (Senior convertible notes due August 15, 2015, USD $)	Sep. 30, 2014	Dec. 31, 2013	Aug. 18, 2010
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013	Aug. 18, 2010
Senior convertible notes due August 15, 2015	'	'	'
Debt Instrument [Line Items]	'	'	'
Principal amount	$100,000	$100,000	$100,000
Unaccreted debt issuance expense	-880	-1,561	'
Net carrying amount	$99,120	$98,439	'

Senior_Convertible_Notes_Addit

Senior Convertible Notes - Additional Information (Detail) (Senior convertible notes due August 15, 2015, USD $)	0 Months Ended
	Aug. 18, 2010	Sep. 30, 2014	Dec. 31, 2013	Aug. 18, 2010
	D	Sep. 30, 2014	Dec. 31, 2013	Aug. 18, 2010
Senior convertible notes due August 15, 2015	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'
Principal amount	'	$100,000,000	$100,000,000	$100,000,000
Senior notes, effective interest rate	'	5.75%	'	5.75%
Accrued interest	'	1,000,000	2,400,000	'
No of convertible shares	147.0859	'	'	'
Principal amount per share	$1,000	'	'	'
Conversion price of shares	'	'	'	$6.80
Percentage of repurchase price	100.00%	'	'	'
Percentage of conversion price equaling stock price	150.00%	'	'	'
Trading days	20	'	'	'
Consecutive trading days	'30 days	'	'	'
Issuance cost	'	'	'	$4,200,000

Accretion_of_Debt_Issuance_Exp

Accretion of Debt Issuance Expense (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Debt Instrument [Line Items]	'	'	'	'
Accretion expense	$231	$216	$681	$637

Components_of_Facility_Agreeme

Components of Facility Agreement (Detail) (USD $)	3 Months Ended		9 Months Ended
Components of Facility Agreement (Detail) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Securities Financing Transaction [Line Items]	'	'	'	'
Accretion of debt discount and debt issuance expense	$231,000	$216,000	$681,000	$637,000
Net carrying value of facility financing obligation	72,625,000	'	72,625,000	'
Commitment asset balance at December 31,2013	5,157,000	'	5,157,000	'
Commitment asset value included in other assets	1,753,000	'	1,753,000	'
Tranche B notes	'	'	'	'
Securities Financing Transaction [Line Items]	'	'	'	'
Tranche B commitment asset fair value	2,921,000	'	2,921,000	'
Tranche 4 and Tranche B	'	'	'	'
Securities Financing Transaction [Line Items]	'	'	'	'
Less commitment asset portion associated with the receipt of Tranche 4 and Tranche B notes	-6,325,000	'	-6,325,000	'
Facility financing obligation	'	'	'	'
Securities Financing Transaction [Line Items]	'	'	'	'
Carrying value	102,300,000	'	102,300,000	'
Principal converted to equity	-93,500,000	'	-93,500,000	'
Accretion of debt discount and debt issuance expense	'	'	7,507,000	'
Facility financing obligation \| Senior convertible notes due December 31, 2019	'	'	'	'
Securities Financing Transaction [Line Items]	'	'	'	'
Debt discount	'	'	2,921,000	'
Facility financing obligation \| Tranche B notes	'	'	'	'
Securities Financing Transaction [Line Items]	'	'	'	'
Carrying value	20,000,000	'	20,000,000	'
Debt discount	'	'	-1,168,000	'
Facility financing obligation \| Fourth tranche	'	'	'	'
Securities Financing Transaction [Line Items]	'	'	'	'
Carrying value	40,000,000	'	40,000,000	'
Debt discount	'	'	($5,435,000)	'

Accretion_of_Debt_Issuance_Cos

Accretion of Debt Issuance Cost and Debt Discount in Connection with Deerfield Financing (Detail) (Deerfield, USD $)	3 Months Ended	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014
Deerfield	'	'
Debt Instrument [Line Items]	'	'
Accretion expense- debt issuance cost	$9	$318
Accretion expense- debt discount	$306	$7,189

Facility_Agreement_Additional_

Facility Agreement - Additional Information (Detail) (USD $)

9 Months Ended

283 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Jul. 01, 2013

Sep. 30, 2014

Jul. 01, 2013

Sep. 30, 2014

Feb. 28, 2014

Sep. 30, 2014

Jul. 01, 2013

Sep. 30, 2014

Jul. 01, 2013

Sep. 30, 2014

Feb. 28, 2014

Sep. 23, 2014

Jul. 18, 2014

6-May-14

Feb. 28, 2014

Mar. 31, 2014

Apr. 30, 2014

Mar. 31, 2014

Sep. 30, 2014

Jul. 01, 2013

Sep. 30, 2014

Tranche B notes

Senior convertible notes due December 31, 2019

Deerfield

Tranche B notes

Milestone Rights Liability

Senior convertible notes due December 31, 2019

Maximum

Notes Issued in Four Equal Tranches

Fourth tranche

Tranche B notes

Tranche Three

Tranche One

Milestone Rights Liability

Tranche One and Tranche Three

Facility Agreement

Tranche

Debt Instrument [Line Items]

Debt facility principal amount

$160,000,000

$90,000,000

Number of equal tranches

Debt facility periodic principal amount

40,000,000

Senior notes, effective interest rate

9.75%

8.75%

9.75%

11.63%

Principal amount of notes purchased

160,000,000

40,000,000

20,000,000

Repayment as a percentage of original principal amount

25.00%

Debt instrument maturity date

31-Dec-19

Maximum secured loan facility

160,000,000

175,000,000

Aggregate principal amount of convertible notes

60,000,000

40,000,000

7,500,000

12,500,000

Common shares issuable upon conversion

18,616,304

12,000,000

Maximum available amount of credit facility under covenant restrictions

25,000,000

Contingent liability for milestone payments

90,000,000

1,900,000

Short term liability

102,300,000

9,200,000

3,200,000

Long term liability

72,625,000

8,900,000

13,100,000

Required payment pursuant to the terms of the Milestone Agreement

5,000,000

Commitment asset at fair value

2,921,000

2,900,000

70,000,000

1,800,000

Amount of common shares issued upon conversion

$93,500,000

$100,000,000

Recovered_Sheet4

Fair Value of Financial Instruments - Additional Information (Detail) (USD $)

9 Months Ended

0 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Sep. 30, 2014

Jul. 01, 2013

Feb. 28, 2014

Dec. 31, 2013

Sep. 30, 2014

Jul. 01, 2013

Sep. 30, 2014

Jul. 18, 2014

6-May-14

Sep. 30, 2014

Tranche B notes

Senior convertible notes due December 31, 2019

Deerfield

Commitment Asset

Milestone Rights Liability

Fair Value, Inputs, Level 3

Senior convertible notes due December 31, 2019

Fair Value, Inputs, Level 3

Tranche B notes

Income Approach Valuation Technique

Tranche B notes

Notes Issued in Four Equal Tranches

Income Approach Valuation Technique

Tranche B notes

Tranche One and Tranche Four Notes

Fair Value of Financial Instruments [Line Items]

Cash equivalents

$172,465,000

$93,803,000

$70,790,000

$61,840,000

Cash equivalents, money market funds

169,700,000

67,700,000

Company's longer-term historical volatility rate

85.00%

Market discount rate

12.70%

11.90%

12.40%

12.00%

17.50%

Fair value of Milestone Rights

23,100,000

Principal amount of notes purchased

40,000,000

20,000,000

160,000,000

Additional commitment asset

2,921,000

2,900,000

1,800,000

Percentage of market yield

11.90%

Commitment asset, debt discount

1,200,000

Transfers of assets between fair value measurement

Transfers of liabilities between fair value measurement

Summary_of_Carrying_Values_and

Summary of Carrying Values and Estimated Fair Values of Notes and Facility Financing Obligation (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Senior convertible notes due August 15, 2015	'	'
Convertible Debt [Line Items]	'	'
Carrying value	$99,120,000	$98,439,000
Estimated fair value	113,900,000	102,200,000
Facility financing obligation	'	'
Convertible Debt [Line Items]	'	'
Carrying value	72,600,000	102,300,000
Estimated fair value	$75,300,000	$107,000,000

Collaborative_Arrangement_Addi

Collaborative Arrangement - Additional Information (Detail) (License and Collaboration Agreement with Sanofi, USD $)	0 Months Ended		3 Months Ended
	Sep. 23, 2014	Aug. 11, 2014	Sep. 30, 2014	Sep. 23, 2014	Aug. 11, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'	'
Up-front fee	'	'	$150,000,000	'	'
Potential milestone payment	'	'	'	'	775,000,000
Profits and losses sharing percentage	'	35.00%	'	'	'
Maximum secured loan facility	'	'	'	175,000,000	'
Senior notes, effective interest rate	'	'	'	8.50%	'
Prepayment of loan percentage of net cash proceeds sale	100.00%	'	'	'	'
Development and Manufacturing Milestone Events	'	'	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'	'
Potential milestone payment	'	75,000,000	'	'	75,000,000
Regulatory Approvals	'	'	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'	'
Potential milestone payment	'	50,000,000	'	'	50,000,000
Product Sales Milestones	'	'	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'	'
Potential milestone payment	'	650,000,000	'	'	650,000,000
Sanofi-Aventis Deutschland GmbH	'	'	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'	'
Profits and losses sharing percentage	'	65.00%	'	'	'
Collaboration revenue recognized	'	'	0	'	'
Deferred revenue	'	'	$150,000,000	'	'